Liver Cirrhoses Clinical Trial
Official title:
Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development: a Multicenter, Double-blind, Placebo Controlled Randomized Clinical Trial
The aim of this study is to assess the efficacy of oral administration of simvastatin plus rifaximin in patients with decompensated cirrhosis to halt the progression of the disease as assessed by prevention of the development of ACLF
The current study was aimed at assessing whether a treatment based on combination of rifaximin and simvastatin would be effective in patients with decompensated cirrhosis to prevent ACLF development Considering that statins have been scarcely investigated in patients with decompensated cirrhosis due to a concern of potential higher liver and muscle toxicity in this population, a first LIVERHOPE_SAFETY clinical trial (unpublished) was undergone to assess safety and toxicity of statins with decompensated cirrhosis. As a preliminary result of the LIVERHOPE_SAFETY clinical trial, it was concluded that the dose of Simvastatin 20mg per day plus Rifaximin is not associated to a higher risk of liver or muscle toxicity in patients with decompensated cirrhosis and simvastatin 20 mg was established for the LIVERHOPE_EFFICACY study. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03219372 -
Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence
|
Phase 2 | |
Recruiting |
NCT03624517 -
Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices
|
Phase 4 | |
Recruiting |
NCT04057287 -
Risk Factors of Liver Fibrosis Among First Degree Relatives of Patients With NASH Related Cirrhosis (NRC)
|
||
Recruiting |
NCT04089878 -
"To Study the Impact of Balloon-occluded Retrograde Transvenous Obliteration (BRTO)/Plug Assisted Retrograde Transvenous Obliteration (PARTO) Mediated Portal Flow Modulation in Reduction of Ammonia and Improvement in Organ Volume and Functionality in Patients of Cirrhosis With LR Shunt
|
N/A | |
Completed |
NCT04212286 -
Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC
|
N/A | |
Completed |
NCT04474743 -
Malnutrition in Chronic Gastrointestinal Diseases, Cross-sectional Study
|
||
Recruiting |
NCT03694691 -
Developing Viability Index for Machine Perfused Livers
|
N/A | |
Terminated |
NCT04072601 -
Statins for Prevention of Disease Progression and Hospitalization in Liver Cirrhosis
|
Phase 4 | |
Terminated |
NCT03878563 -
Alterations in Intestinal Mucosal Barrier Visualized by Confocal Laser Endomicroscopy in Liver Cirrhosis: a Pilot Trial (AMBIC)
|
||
Terminated |
NCT04160039 -
Early Cycle Ergometry for Critically-Ill Liver Failure Patients in a Transplant Intensive Care Unit
|
N/A | |
Recruiting |
NCT04191369 -
EGD vs EUS in Diagnosing Portal Hypertension in Cirrhotic Patients.
|
N/A | |
Completed |
NCT03083925 -
Viatorr CX Case-control Study for Complications of Portal Hypertension
|
||
Not yet recruiting |
NCT03855709 -
Antibiotic-resistant Bacterial Infection of Hepatic Patients
|
||
Recruiting |
NCT02484573 -
Evaluation of Intestinal Permeability in Cirrhotic Patients Before and After Treatment With Non-selective Beta Blocker (Propranolol)
|
N/A | |
Recruiting |
NCT04357600 -
Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B
|
Phase 1/Phase 2 | |
Completed |
NCT03156426 -
Prognostic Biomarkers For Acute Kidney Injury In Liver Cirrhosis
|
||
Active, not recruiting |
NCT03868397 -
Preoperative Portal and Splanchnic Flow Measurement Using MRI
|
N/A | |
Terminated |
NCT03650660 -
Concordance Between Echocardiographic Assessment Performed in the Initial Phase of Decompensated Cirrhosis With Edema and Ascites by an Expert Intensive Care Physician and a Non-expert Gastroenterologist
|
||
Completed |
NCT03871894 -
Indirect Calorimeter Based Study in Patients With Liver Cirrhosis
|
N/A | |
Completed |
NCT03283176 -
Hematologic Profile, Vit. B12 and Folic Acid in Cirrhotics Received Sofosbuvir and Daclatasvir With or Without Ribavirin
|